Head-to-head evidence
aleniglipron vs GZR18
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
aleniglipron
Developed by Structure Therapeutics
NCT06703021 · Phase 2 · completed
The study was randomized, triple-blind, and placebo-controlled, with 85 participants. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Registered primary outcomes are safety measures; the weight-loss figures are the trial's prespecified efficacy readout, reported in the sponsor's topline press release and not yet peer reviewed. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: September 2028 · NCT07654361 (registry estimate)
GZR18
Developed by Gan & Lee Pharmaceuticals
NCT06737042 · Phase 2 · completed
The study randomized 326 participants and used quadruple masking with placebo and tirzepatide comparator arms; its primary endpoint was the clinical outcome of percentage change in body weight. Because the primary comparison has not yet been reported, it cannot establish whether GZR18 met its efficacy objective.
Next expected readout: June 2027 · NCT07150975 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: aleniglipron's landscape · GZR18's landscape